Status:

TERMINATED

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Lead Sponsor:

Beth Israel Deaconess Medical Center

Collaborating Sponsors:

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tu...

Detailed Description

TUMOR COLLECTION: Tumor cells will be collected from the participant to make the study vaccine. Based on the location of the tumor, a decision will be made as to the best approach to obtain these cell...

Eligibility Criteria

Inclusion

  • Stage IV breast cancer with measurable disease and accessible tumor
  • ECOG Performance Status 0-2 with greater than six week life expectancy
  • 18 years of age or older
  • Laboratory values as outlined in the protocol

Exclusion

  • Patients must not have received other immunotherapy treatment in the three months prior to the initial vaccination
  • Patients may not be on herceptin therapy during this protocol and may not have received it for four weeks prior to initial vaccination
  • Patients must not have received weekly chemotherapy or hormonal treatment for two weeks prior to the initial vaccination and must not have received monthly chemotherapy for four weeks prior to the initial vaccination
  • Clinical evidence of CNS disease
  • Clinically significant autoimmune disease
  • Patients who are HIV+
  • Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Pregnant of lactating women will be excluded, all premenopausal women must undergo pregnancy testing

Key Trial Info

Start Date :

December 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT00622401

Start Date

December 1 2009

End Date

October 1 2014

Last Update

November 14 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215